{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:37Z","timestamp":1792685977017,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006010","name":"Bayer Schering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.msard.2021.102983","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T02:37:33Z","timestamp":1620095853000},"page":"102983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab"],"prefix":"10.1016","volume":"52","author":[{"given":"Fabio","family":"Buttari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Dolcetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Azzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bellantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102983_bib0001","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102983_bib0002","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","article-title":"What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.msard.2021.102983_bib0003","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-021-10463-3","article-title":"Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab","author":"Khayat-Khoei","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102983_bib0004","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","article-title":"Neurological immunotherapy in the era of COVID-19 \u2014 looking for consensus in the literature","volume":"16","author":"Korsukewitz","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2021.102983_bib0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.msard.2019.04.004","article-title":"Immunization and multiple sclerosis: recommendations from the French multiple sclerosis society","volume":"31","author":"Lebrun","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102983_bib0006","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.102983_bib0007","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/vaccines9020099","article-title":"Multiple sclerosis and SARS-CoV-2 vaccination: considerations for immune-depleting therapies","volume":"9","author":"Sellner","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.msard.2021.102983_bib0008","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani, Maria","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.102983_bib0009","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1212\/NXI.0000000000000409","article-title":"Immune response to vaccines is maintained in patients treated with dimethyl fumarate","volume":"5","author":"von Hehn","year":"2018","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102983_bib0010","article-title":"COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response","volume":"14690","author":"Zabalza","year":"2021","journal-title":"Eur. J. Neurol. ene."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:44Z","timestamp":1761901004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":10,"alternative-id":["S2211034821002509"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102983","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102983"}}